AURN001 demonstrates improvement of visual acuity in patients with corneal endothelial dysfunction. The CLARA trial demonstrates favorable safety profiles across all treatment arms. The Latest The ...
1. Invasive disease-free survival occurred in 19.7% of the T-DM1 group and 32.2% in the trastuzumab group, with an HR of 0.54 (significant). 2. Investigator-adjudicated trial-related adverse events of ...
1. Deep neuromuscular blockade in radiofrequency catheter ablation under general anesthesia reduced the atrial fibrillation recurrence rate compared to moderate neuromuscular blockade This randomized ...